Description
Description:
Vivitra is an injectable medication manufactured by Zydus Ingenia, containing the active ingredient Trastuzumab. It is formulated as a sterile solution for intravenous infusion and is available in vials containing 440 mg of Trastuzumab.
Indications:
Vivitra (Trastuzumab) is indicated for the treatment of various types of cancer, including:
- Breast Cancer:
- Vivitra is used in combination with chemotherapy as adjuvant treatment for HER2-positive early breast cancer that has spread to lymph nodes, or is hormone receptor-negative, or both, after surgery.
- It is also used as a single agent for the treatment of HER2-positive metastatic breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
- Gastric Cancer:
- Vivitra is indicated for the treatment of HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma, in combination with chemotherapy.
Mechanism of Action:
Trastuzumab, the active ingredient in Vivitra, is a monoclonal antibody that targets the HER2 (human epidermal growth factor receptor 2) protein, which is overexpressed in certain types of cancer cells, particularly breast and gastric cancers. Trastuzumab binds to the HER2 receptor, inhibiting its signaling pathways and blocking the growth and survival of cancer cells. Additionally, Trastuzumab can stimulate the immune system to attack HER2-positive cancer cells, further enhancing its anti-cancer effects.
Dosage and Administration:
- The dosage of Vivitra (Trastuzumab) is determined by the healthcare provider based on factors such as the patient’s body weight, overall health, and the specific type and stage of cancer being treated.
- It is administered intravenously over a specified period, typically in a hospital or clinical setting.
- Vivitra may be given alone or in combination with other chemotherapy drugs, depending on the treatment regimen prescribed by the healthcare provider.
Potential Side Effects:
- Common side effects of Vivitra may include:
- Fever
- Chills
- Nausea and vomiting
- Diarrhea
- Fatigue
- Headache
- Muscle pain
- Serious side effects can occur, including:
- Cardiotoxicity (heart problems)
- Infusion-related reactions
- Pulmonary toxicity
- Hepatotoxicity (liver problems)
- Hypersensitivity reactions
- Immune-mediated adverse reactions
Precautions:
- Vivitra should be used with caution in patients with pre-existing heart or lung conditions.
- Regular monitoring of cardiac function and other relevant parameters may be necessary during treatment with Vivitra.
- Patients should inform their healthcare provider about any medications, supplements, or herbal products they are taking before starting treatment with Vivitra.
Note:
Vivitra (Trastuzumab) is an important medication in the treatment of HER2-positive breast and gastric cancers. Its use should be under the supervision of a qualified oncologist, and patients are advised to follow their healthcare provider’s recommendations closely for optimal safety and efficacy.
Reviews
There are no reviews yet.